TIGIT can interact with poliovirus receptor (PVR, CD155) on DCs to induce IL-10 secretion for suppressing the Th1 T-cell response, inhibiting the NF-κB pathway and preventing the effective cytotoxic immune response, which is required to reject the tumour [107]. Here, TIGIT is linked to neoplasm.